A Fosinopril
Mylanta (probably containing aluminium/magnesium hydroxide) reduces the bioa- vailability of
fosinopril by about one-third.
The manufacturers suggest separating its dosing from that of
antacids by at least 2 hours.
Antacids are said to reduce the bioavailability of a number of
ACE inhibitors but this seems unlikely to be clinically important (except perhaps in the case of
fosinopril, see above).
Several manufacturers of
ACE inhibitors warn that
antacids may reduce their bioavailability, but there seems to be no evidence of a clinically significant interaction in practice.